The biotech finance sector remains in retroactive mode, with money reaching shareholders and companies through corporate mergers and deals rather than through venture capital or public market financing.
8 billion, Merck paid an 81% premium for Prometheus Bioscience and its anti-inflammatory assets. Meanwhile, the quarter’s top venture round went to ElevateBio, a gene therapy platforms provider, with a series D round that brought another $401 million to the substantial venture capital stack raised by the company since 2019.
Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen: